Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Vertex was the first company to produce a medicine tackling the root cause of cystic fibrosis (CF) – mutations in a gene that codes for ion channels in cells that produce mucus, sweat ...

Vertex could be close to a price deal with the NHS over its portfolio of cystic fibrosis drugs, after health ministers wrote to the US firm asking for a conclusion to talks after almost two years ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

The latest CNBC CFO Council Survey found that 60% of CFOs expect a U.S. recession later in 2025. Another 15% predict a ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Learn more about whether Moderna, Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.